Idiopathic Pulmonary Fibrosis Clinical Trial
— OSCILLOOfficial title:
Impulse Oscillometry for Prognostication in Idiopathic Pulmonary Fibrosis
Verified date | November 2021 |
Source | University Hospital, Tours |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
A 5-point decline of forced vital capacity expressed as % predicted, over 6 months, is the current definition of disease progression (fast decline in lung function) in idiopathic pulmonary fibrosis. There is a need for techniques allowing to characterize disease progression earlier, so that treatment may be adapted as early as possible in the lack of a response. Hypothesis. Our hypothesis is that 3-month changes of lung function parameters measured by a novel technique, impulse oscillometry, predicts 6-month changes in forced vital capacity in idiopathic pulmonary fibrosis.
Status | Completed |
Enrollment | 54 |
Est. completion date | September 27, 2021 |
Est. primary completion date | September 27, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 45 Years and older |
Eligibility | Inclusion Criteria: - Age = 45 years. - Idiopathic Pulmonary Fibrosis defined Interstitial Lung Diseases with 1) lack of any known cause for Interstitial Lung Diseases and 2) either the "definite usual interstitial pneumonia" pattern at CT scan, or the usual interstitial pneumonia (definite, probable or possible) pattern at lung biopsy, according to the Lung Function Group of the French Pulmonology Society criteria. Exclusion Criteria: - History of chronic obstructive airway disease. - History of congestive heart failure. - Emphysema-fibrosis syndrome, defined as emphysematous lesions involving >15% of the lung area at the level of the aortic arch (upper lobes). - History of lower respiratory infection or acute respiratory failure of any cause less than 90 days before inclusion. - Opposition to data processing. |
Country | Name | City | State |
---|---|---|---|
France | Respiratory Functional Explorations, University Hospital, Lille | Lille | |
France | Respiratory Functional Explorations, University Hospital, Nantes | Nantes | |
France | Department of digestive physiology, urinary, respiratory and exercise, University Hospital, Rouen | Rouen | |
France | Pulmonology Department, University Hospital, Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Performance of the 5-Hz reactance of the respiratory system (Xsr5) variation at 3 months, for the diagnosis of rapid decline in lung function. | Receiver operating characteristics curves will be used to determine diagnostic performance. | Baseline, 3 months, 6 months | |
Secondary | Performance of the 3-month variation in additional impulse oscillometry parameters for the diagnosis of rapid decline in lung function | Receiver operating characteristics curves will be used to determine diagnostic performance. | Baseline, 3 months, 6 months | |
Secondary | Performance of baseline impulse oscillometry parameters for the diagnosis of rapid decline in lung function | Receiver operating characteristics curves will be used to determine diagnostic performance. | Baseline, 3 months, 6 months | |
Secondary | Assess correlations between impulse oscillometry parameters and forced vital capacity | Forced vital capacity is the total amount of air exhaled during the Forced expiratory volume test (how much air a person can exhale during a forced breath) | Baseline, 3 months, 6 months | |
Secondary | Assess correlations between impulse oscillometry parameters and exertional dyspnea | Dyspnea is assessed by the baseline dyspnea questionnaire and the transitional dyspnea questionnaire | Baseline, 3 months, 6 months | |
Secondary | Assess correlations between impulse oscillometry parameters and the extent of either fibrosis or emphysema lesions on CT scans | Lesions are scored by trained observers. | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05984992 -
The First-in-human Study of SRN-001 in Healthy Participants
|
Phase 1 | |
Active, not recruiting |
NCT04312594 -
Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT03865927 -
GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Completed |
NCT03979430 -
Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study
|
N/A | |
Enrolling by invitation |
NCT04905693 -
Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 3 | |
Not yet recruiting |
NCT06241560 -
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
|
Phase 2 | |
Terminated |
NCT04419558 -
Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 3 | |
Completed |
NCT03725852 -
A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
Terminated |
NCT03573505 -
An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
Recruiting |
NCT04148157 -
Quality of Life in IPF - Patient and Physician Perceptions
|
||
Completed |
NCT03222648 -
Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis
|
N/A | |
Not yet recruiting |
NCT06422884 -
A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)
|
Phase 2 | |
Completed |
NCT02257177 -
RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02268981 -
Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF)
|
N/A | |
Withdrawn |
NCT01524068 -
A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations
|
Phase 2 | |
Enrolling by invitation |
NCT01382368 -
Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients
|
Phase 4 | |
Completed |
NCT01199887 -
Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
Completed |
NCT01110694 -
Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
|
||
Active, not recruiting |
NCT02951416 -
Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
|
||
Terminated |
NCT00981747 -
Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis
|
Phase 2/Phase 3 |